EXHIBIT 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Corbus Pharmaceuticals Holdings, Inc.
(Exact Name of Registrant as Specified in its Charter)
Newly Registered Securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Security Type |
|
Security Class Title |
|
Fee Calculation Rule |
|
Amount Registered |
|
Proposed Maximum Offering Price Per Share |
|
Maximum Aggregate Offering Price |
|
Fee Rate |
|
Amount of Registration Fee |
Equity |
|
Common Stock, $0.0001 par value per share |
|
457(o) |
|
(1) |
|
(1) |
|
(1) |
|
|
|
|
Equity |
|
Preferred Stock, $0.0001 par value per share |
|
457(o) |
|
(1) |
|
(1) |
|
(1) |
|
|
|
|
Debt |
|
Debt Securities |
|
457(o) |
|
(1) |
|
(1) |
|
(1) |
|
|
|
|
Other |
|
Warrants |
|
457(o) |
|
(1) |
|
(1) |
|
(1) |
|
|
|
|
Other |
|
Units |
|
457(o) |
|
(1) |
|
(1) |
|
(1) |
|
|
|
|
Other |
|
Subscription Rights |
|
457(o) |
|
(1) |
|
(1) |
|
(1) |
|
|
|
|
Unallocated (Universal) Shelf |
|
--- |
|
457(o) |
|
(1) |
|
(1) |
|
$15,752,564 |
|
0.00014760 |
|
$2,325.08 |
Total Offering Amounts |
|
|
|
$15,752,564 |
|
|
|
$2,325.08 |
||||||
Total Fees Paid Previously |
|
|
|
|
|
|
|
— |
||||||
Total Fee Offsets |
|
|
|
|
|
|
|
— |
||||||
Net Fee Due |
|
|
|
|
|
|
|
$2,325.08 |
(1) |
The Registrant previously registered the offer and sale of certain securities having a proposed maximum aggregate offering price of $100,000,000 pursuant to a Registration Statement on Form S-3 (File No. 333-272314) (the “Prior Registration Statement”), which was initially filed on June 1, 2023 and declared effective by the Securities and Exchange Commission on June 13, 2023. As of the date hereof, a balance of $78,762,823 of such securities remains unsold under the Prior Registration Statement. In accordance with Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the registrant is hereby registering the offer and sale of an additional $15,752,564 of its Securities. The additional amount of Securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement. |